VERQUVO has been extensively and specifically evaluated in the VICTORIA study, demonstrating powerful efficacy in chronic heart failure (HF) patients following a worsening HF event.


VICTORIA is the first positive outcome Phase III clinical study to focus exclusively on patients with chronic heart failure (HF) following a worsening HF event.

  • VERQUVO delivers a superior annual ARR of 4.2% for cardiovascular (CV) death and HF hospitalization combined, compared to background therapies alone.
  • The number needed to treat (NNT) with VERQUVO for one year to prevent a primary outcome event is approximately 24.
     

CV death and HFH combined

CV death and HFH combined

The VICTORIA study involved
5,050 patients
with chronic HF in
600 centers
, in
42 countries
, across the globe.

Improve your patients’ chances of staying alive and out of hospital following a worsening HF event by adopting a therapy that will significantly reduce their risk of another event.

 

Risk of CV death or HFH stratified by baseline NT-proBNP quartiles

Risk of CV death or HFH stratified by baseline NT-proBNP quartiles

The VICTORIA study is different from other contemporary HF studies

In the VICTORIA study, VERQUVO was investigated in a patient population that had been insufficiently studied in other contemporary HF trials.

  • 90% of patients were already on at least 2 guideline-based HF therapies.
  • 60% received triple therapy, including ACEI/ARNIs, ARBs, beta blockers and MRAs.

The primary outcome was a composite of death from CV causes or first hospitalization for HF.

VICTORIA study parameters

VICTORIA study parameters2,7

The VICTORIA study shows that VERQUVO, when added to background therapies, can reduce the combined risk of CV death and HF hospitalization following a worsening HF event.